Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA)

SUNPHARMA Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Revenue	492,088	484,969	438,857	386,545	334,981	328,375
Revenue Growth (YoY)	9.20%	10.51%	13.53%	15.39%	2.01%	12.98%
Cost of Revenue	113,594	114,422	113,187	108,761	92,185	96,796
Gross Profit	378,493	370,547	325,670	277,784	242,796	231,579
Selling, General & Admin	95,551	95,025	83,549	73,544	69,042	63,986
Other Operating Expenses	148,893	144,755	123,779	101,331	88,678	97,587
Operating Expenses	270,046	265,345	232,613	196,223	178,520	182,101
Operating Income	108,447	105,202	93,058	81,560	64,276	49,478
Interest Expense	-2,191	-2,385	-1,720	-1,274	-1,414	-3,027
Interest & Investment Income	11,262	11,262	5,310	7,687	4,672	4,108
Earnings From Equity Investments	-417.6	-384.1	-479	-165.4	-123.3	-148.3
Currency Exchange Gain (Loss)	-163.6	361.3	-1,261	1,540	236.5	156.1
Other Non Operating Income (Expenses)	4,852	1,571	756.5	735.9	2,895	1,828
EBT Excluding Unusual Items	121,788	115,627	95,664	90,084	70,542	52,394
Merger & Restructuring Charges	-232.1	-232.1	-643.9	-563.5	-	-
Gain (Loss) on Sale of Investments	-102	-102	-240.3	7.7	260	0.4
Gain (Loss) on Sale of Assets	-99.7	-99.7	75.4	347.5	138.8	-52.2
Asset Writedown	-72	-1,564	-312.5	-2,179	-155.5	-1.5
Legal Settlements	-	-	-	-1,563	-895.6	-1,043
Other Unusual Items	-1,482	-3,219	-1,071	-41,657	-42,166	-1,564
Pretax Income	119,885	110,495	93,605	44,648	27,870	49,948
Income Tax Expense	15,236	14,395	8,476	10,755	5,147	8,228
Earnings From Continuing Operations	104,649	96,100	85,129	33,893	22,724	41,720
Minority Interest in Earnings	-754.3	-336.5	-393.6	-1,166	6,315	-4,070
Net Income	103,895	95,764	84,736	32,727	29,038	37,649
Net Income to Common	103,895	95,764	84,736	32,727	29,038	37,649
Net Income Growth	23.17%	13.01%	158.91%	12.70%	-22.87%	41.25%
Shares Outstanding (Basic)	2,398	2,399	2,399	2,399	2,399	2,399
Shares Outstanding (Diluted)	2,398	2,399	2,399	2,399	2,399	2,399
Shares Change (YoY)	-0.17%	-	-	-	-	0.00%
EPS (Basic)	43.32	39.91	35.32	13.64	12.10	15.69
EPS (Diluted)	43.31	39.90	35.30	13.60	12.10	15.69
EPS Growth	23.40%	13.03%	159.56%	12.40%	-22.89%	41.37%
Free Cash Flow	-	99,332	28,738	74,895	50,002	50,128
Free Cash Flow Per Share	-	41.40	11.98	31.21	20.84	20.89
Dividend Per Share	-	13.500	11.500	10.000	7.500	4.000
Dividend Growth	-	17.39%	15.00%	33.33%	87.50%	45.45%
Gross Margin	76.92%	76.41%	74.21%	71.86%	72.48%	70.52%
Operating Margin	22.04%	21.69%	21.20%	21.10%	19.19%	15.07%
Profit Margin	21.11%	19.75%	19.31%	8.47%	8.67%	11.47%
Free Cash Flow Margin	-	20.48%	6.55%	19.38%	14.93%	15.27%
EBITDA	132,031	128,760	116,513	101,536	83,451	68,567
EBITDA Margin	26.83%	26.55%	26.55%	26.27%	24.91%	20.88%
D&A For EBITDA	23,584	23,559	23,456	19,975	19,175	19,089
EBIT	108,447	105,202	93,058	81,560	64,276	49,478
EBIT Margin	22.04%	21.69%	21.20%	21.10%	19.19%	15.07%
Effective Tax Rate	12.71%	13.03%	9.05%	24.09%	18.47%	16.47%
Revenue as Reported	508,911	498,510	445,202	395,760	343,337	334,735

Source: S&P Capital IQ. Standard template. Financial Sources.